Betatrophin/Lipasin/C19orf80: In Silico Approach for Protein-Based Biomaterial Marker in Metabolic Syndrome and Colorectal Cancer Through Computational-Based Study

This computational material-based study aimed to provide a comprehensive data with the molecular interaction between betatrophin and its target as the confirmation of the primary role of betatrophin on serological lipid profile alteration and metabolic syndrome progression. We analyzed the binding behavior of betatrophin and LPL using docking model. The underlying molecular interaction between betatrophin and lipoprotein lipase (LPL) binding site results in the inhibitory activity of betatrophin on LPL. Our in Silico data showed that betatrophin could regulate that essential enzyme and suggested indirectly to restrict TG level during the circadian cycle in the human circulation. To sum up, betatrophin or RIFL shows as a promising future early biomarker for obesity and cancer linked metabolic syndrome. Hence, this preliminary computational material analysis data provided a hallmark for the future development of betatrophin as the clinical biomaterial marker in metabolic syndrome and gastrointestinal cancer.